Sulodexide versus Calcium Heparin in the medium-term treatment of deep vein thrombosis of the lower limbs

Angiology

Volumn 48, Issue 9, 1997, Pages 805-811

  Pinto, Antonio ^a,b   Corrao, Salvatore ^a   Galati, Domenico ^a   Arnone, Sabrina ^a   Licata, Anna ^a   Parrinello, Gaspare ^a   Maniscalchi, Tiziana ^a   Licata, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; HEPARIN CALCIUM; SULODEXIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; FEMALE; HEMATOMA; HUMAN; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; LEG THROMBOSIS; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SYMPTOMATOLOGY; VENOUS PRESSURE;

EID: 0030767151     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979704800907     Document Type: Article

References (47)

1. Goldhaber GZ: Epidemiology of pulmonary embolism and deep vein thrombosis. Blood Hemostas Thromb 59:1327-1336, 1994.
2. Anderson FA, Wheeler HB, Goldberg RJ, et al: A population-based perspective on the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism. The Worchester Study. Arch Intern Med 151:933-938, 1991.
3. Haake DA, Berkman SA: Venous thromboembolic disease after hip surgery. Risk factors, prophylaxis and diagnosis. Clin Orthop 242:212-231, 1989.
4. Kieregaard A, Norgren L, Olsson GC, et al: Incidence of deep vein thrombosis in bedridden nonsurgical patients. Acta Med Scand 222:409-414, 1987.
5. Gerstman BB, Piper JM, Tomida DK, et al: Oral contraceptive oestrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133:32-37, 1991.
6. Prentice CRM: Pathogenesis of thrombosis. Hemostasis 20 (suppl 1):50-59, 1990.
7. Lagerstedt CJ, Olssin CG, Fagher BO, et al: Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 2:515-518, 1985.
8. Wilson JE, Bynum LJ, Parkey RW: Heparin therapy in venopus thromboembolism. Am J Med 70:808-816, 1981.
9. Linn BJ, Mazza JJ, Friedenberg WR: Treatment of venous thromboembolic disease: A pragmatic approach to anticoagulation and thrombolysis. Postgrad Med 79:171-178, 1986.
10. Rosenberg DR, Lam L: Correlation between structure and function of heparin. Proc Natl Acad Sci USA 76: 1218-1222, 1979.
11. Preissner KT: Physiological role of vessel wall related antithrombotic mechanisms: Contribution of endogenous and exogenous heparin-like components to the anticoagulant potential of the endothelium. Hemostasis 20:1-19, 1990.
12. Caramelli L, Mirchioni R, Carini A: Effectiveness of short-term Sulodexide treatment on peripheral vascular disease clinical manifestations. Eur Rev Med Pharmacol Sci 10:55-58, 1988.
13. Castelluccio A, Bologna E: Effect of Sulodexide on blood viscosity in patients with peripheral vascular disease. Curr Med Res Opin 12:325-331, 1991.
14. Ciuffetti G, Mercuri M, Susta A, et al: Effects of 3-glycosaminoglycan sulphate on hemorheologic parameters in hyperlipidemic peripheral vascular disease (PVD) patients: A preliminary double-blind crossover study. Angiology 40:255-259, 1989.
15. Cospite M, Milio G, Ferrara F, et al: Double-blind study of the pharmacological effects of Sulodexide in patients with multiple atherosclerotic vascular disease. Eur Rev Med Pharmacol Sci 7:97-106, 1985.
16. Crepaldi G, Fellin R, Calabró A, et al: Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use. Atherosclerosis 81:233-242, 1990.
17. De Giglio V, Guida C: Prevention of vascular complications from immobility using Sulodexide. Med Praxis 11:1-8, 1990.
18. Della Marchina M, Bellucci M, Palazzini E: Mediumterm oral Sulodexide treatment in diabetic patients suffering from peripheral arterial obstructive disease: A double-blind, placebo-controlled study. Prog Rep 4:5-15, 1992.
19. Luttichau U, Palazzini E: Pharmacological treatment of postphlebitic syndromes with Sulodexide. Med Praxis 13:1-8, 1992.
20. Pisano L, Moronesi F, Falco F, et al: The use of Sulodexide in the treatment of peripheral vasculopathy accompanying metabolic diseases. Thromb Res 41:23-31, 1986.
21. Verardi S, Ippoliti A, Ramundo A, et al: Medium-term treatment of chronic venous insufficiency with oral Sulodexide. Aggiorn Med Chir 11:230-240, 1992.
22. Andriuoli G, Mastacchi R, Barbanti M: Antithrombotic activity of a glycosaminoglycan (Sulodexide) in rats. Thromb Res 34:81-86, 1984.
23. Barbanti M, Guizzardi S, Calanni F, et al: Antithrombotic and thrombolytic activity of Sulodexide in rats. Int J Clin Lab Res 22:179-184, 1992.
24. Agrati AM, Mauro M, Savasta C, et al: A double-blind, cross-over, placebo-controlled study of the profibrinolytic and antithrombotic effects of oral Sulodexide. Adv Ther 9:147-155, 1992.
25. Crepaldi G, Rossi A, Coscetti G, et al: Sulodexide oral administration influences blood viscosity and fibrinolysis. Drugs Exp Clin Res 18:189-195, 1992.
26. Mauro M, Ferraro G, Palmieri GC: Profibrinolutic and antithrombotic effects of Sulodexide oral administrator: A double-blind, cross-over, placebo-controlled study. Curr Ther Res 51:342-350, 1992.
27. Messa GL, La Placa G, Puccetti L, et al: Pharmacodynamic effects of Sulodexide on profibrinolytic and hemorrheological patterns. Clin Drug Invest 10:165-171, 1995.
28. Fiore G, Baraldi A, Gambarotta C, et al: Inhibition of plasminogen activator inhibitor (PAI-1) by Sulodexide in postthrombophlebitic patients. J Drug Devel 3:173-178, 1991.
29. Mannarino E, Pasqualini L, Ciuffetti G, et al: Effect of oral administration of Sulodexide on fibrinolysis and plasma viscosity. Drug Invest 4:346-350, 1992.
30. Romano F, Platania M, Costa A, et al: The effect of Sulodexide on blood viscosity in patients with peripheral vascular disease. Eur J Clin Res 3:73-82, 1992.
31. Lunetta M, Salanitri T: Lowering of plasma viscosity by the oral administration of the glycosaminoglycan Sulodexide in patients with peripheral vascular disease. J Intl Med Res 20:45-53, 1992.
32. Condorelli M, Chiariello M, Dagianti A, et al: IPO-V2: A prospective, multicenter, randomized, comparative clinical investigation of the effects of Sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol 23:27-34, 1994.
33. Palmieri GC, Ambrosi G, Nazzari M, et al: The influence of Sulodexide on some coagulation parameters: A pharmacokinetic study. Clot Hemat Malign 2:7-13, 1984.
34. Palazzini E, Procida C: Effects of some mucopolysaccharides on activated Factor X. Biochem Pharmacol 27:608-610, 1975.
35. Busutti L, Breccia A: Pharmacokinetics of Sulodexide after single oral administration in man. Eur J Clin Res 1:25-36, 1991.
36. Breccia A, Busutti L, Fini A: Pharmacokinetics of Sulodexide evaluated from labelled fast-moving heparin and from labelled dermatan sulphate after single intravenous and oral administration in man. Eur J Clin Res 3:97-112, 1992.
37. 131I-labelled fast-moving heparin after single intravenous and oral administration in man at different doses. Br J Clin Res 3:161-178, 1992.
38. Silvestro L, Lanzarotti E, Marchi E, et al: Human pharmacokinetics of glycosaminoglycans using deuterium-labeled and unlabeled substances: Evidence for oral absorption. Sem Thromb Hemost 20:281-292, 1994.
39. Messmore HL, Bishop M, Wehrmacher WH: Acute venous thrombosis. Therapeutic choices for superficial and deep veins. Postgrad Med 89:73-77, 1991.
40. Hirsh J: Drug therapy: Heparin. N Engl J Med 324: 1565-1574, 1991.
41. Lensing AWA, Hirsh J: Rationale and results of thrombolytic therapy for deep vein thrombosis. Thromb Res 65:268A-273A, 1992.
42. Levine M, Hirsh J: Hemorrhagic complications of anticoagulant therapy. Semin Thromb Hemost 12:39-57, 1986.
43. Lopaciuk S, Meissner AJ, Filipecki S, et al: Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial. Thromb Hemostas 68:14-18, 1992.
44. Duroux P, Ninet J, Collaborative European Multicentre Study: A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Hemostas 65:251-256, 1991.
45. Prandoni P, Meduri F, Cuppini S, et al: Dermatan sulphate: A safe approach to prevention of post-operative deep vein thrombosis. Br J Surg 79:505-509, 1992.
46. Agnelli G, Cosmi B, Di Filippo P, et al: A randomized, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Hemostas 67:203-208, 1992.
47. Buchanan M, Liao P, Smith L, et al: Prevention of thrombus formation and growth by Antithrombin III and Heparin Cofactor II-dependent thrombin inhibitors: Importance of Heparin Cofactor II. Thromb Res 74:463-475, 1994.